Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mini-Review

Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts

Bone Marrow Transplantation volume 28, pages 725–735 (2001)Cite this article

Abstract

Autologous stem cell transplantation appears to enhance outcome in multiple myeloma patients. To improve upon these results, various groups have utilized tandem autografts, as well as used reduced-conditioning allogeneic stem cell transplantation. These two approaches, discussed herein, have been promising. Inherent patient selection, however, appears to play a role and much of the data have not yet been subjected to peer-review scrutiny. At present, these strategis remain investigational and cannot be considered the standard-of-care for multiple myeloma patients. Bone Marrow Transplantation (2001) 28, 725–735.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New Engl J Med 1996 335: 91–97

    CAS  PubMed  Google Scholar 

  2. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres Br J Haematol 2001 113: 209–216

    CAS  PubMed  Google Scholar 

  3. Rajkumar SV, Hayman S, Fonseca R et al. Thalidomide plus dexamethasone (THAL/DEX) and thalidomide alone (THAL) as first line therapy for newly diagnosed multiple myeloma (MM) Blood 2000 96: (Suppl. 1) 168a (Abstr. 722)

    Google Scholar 

  4. Barlogie B, Spencer T, Tricot G et al. Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma Blood 2000 96: (Suppl. 1) 514a (Abstr. 2213)

    Google Scholar 

  5. Moreau P, Milpied N, Mahe B et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma Bone Marrow Transplant 1999 23: 1003–1006

    CAS  PubMed  Google Scholar 

  6. Phillips GL, Meisenburg B, Hale GA et al. Amifostine (AF) cytoprotection (CP) of escalating doses of melphalan (MEL) and autologous hematopoietic stem cell transplantation (AHSCT): final results of a phase I and II study Proc Am Soc Clin Oncol 2001 20: 7a (Abstr. 24)

    Google Scholar 

  7. Bensinger B, Giralt S, Eary J et al. 166Holmium-DOTMP plus standard high dose chemotherapy (HDC) with autologous transplant produce high rates of complete remission (CR) in multiple myeloma (MM) patients: an updated report of a phase I/II study Proc Am Soc Clin Oncol 2001 20: 5a (Abstr. 18)

    Google Scholar 

  8. Dispenzeri A, Wiseman GA, Lacy MQ et al. A phase I study of a conditioning regimen for peripheral stem cell transplantation (PBSCT) for multiple myeloma (MM): 153samarium ethylenediaminetetramethylenephosphonate (153SM-EDTMP) and melphalan Blood 2000 96: (Suppl. 1) 558a (Abstr. 2397)

    Google Scholar 

  9. Byrne JL, Carter GI, Bienz N et al. Adjuvant α-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma Bone Marrow Transplant 1998 22: 639–643

    CAS  PubMed  Google Scholar 

  10. Massaia M, Borrione P, Battaglio S et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy Blood 1999 94: 673–683

    CAS  PubMed  Google Scholar 

  11. Kwak L . Tumor vaccination strategies combined with autologous peripheral stem cell transplantation Ann Oncol 1998 9: S41–S46

    PubMed  Google Scholar 

  12. Kwak LW, Taub DD, Duffy DL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised donor Lancet 1995 345: 1016–1020

    Article  CAS  PubMed  Google Scholar 

  13. Stevenson FK, King CA, Spellerberg MB et al. DNA vaccines against haematological malignancies Haematologica 1999 84: 11–13

    PubMed  Google Scholar 

  14. Munshi NC, Barlogie B, Desikan KR, Wilson C . Novel approaches in myeloma therapy Semin Oncol 1999 26 (5 Suppl. 13): 28–34

    Google Scholar 

  15. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma New Engl J Med 1999 341: 1565–1571

    CAS  PubMed  Google Scholar 

  16. Trudel S, Li Z, Dodgson C et al. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma – a phase 1 study Leukemia 2001 15: 846–854

    CAS  PubMed  Google Scholar 

  17. Margolin K, Forman SJ . Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy Cancer J Sci Am 2000 6: (Suppl. 1) S33–S38

    PubMed  Google Scholar 

  18. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation Blood 1996 87: 2195–2204

    CAS  PubMed  Google Scholar 

  19. Moreau P, Harousseau JL, Wijdenes J et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma Br J Haematol 2000 109: 661–664

    CAS  PubMed  Google Scholar 

  20. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma Biol Blood Marrow Transplant 2000 6: 621–627

    CAS  PubMed  Google Scholar 

  21. Dowlati A, Robertson K, Ksenich P et al. Phase I trial of combination bryostatin-1 and vincristine in B-cell malignancies Proc Am Soc Clin Oncol 2000 19: 215a (Abstr. 837)

    Google Scholar 

  22. Fonseca R, Oken MM, Harrington D et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy Leukemia 2001 15: 981–986

    CAS  PubMed  Google Scholar 

  23. Shaughnessy J, Tian E, Sawyer J et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH Blood 2000 96: 1505–1511

    CAS  PubMed  Google Scholar 

  24. Facon T, Avet-Loiseau H, Guillerm G et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy Blood 2001 97: 1566–1571

    CAS  PubMed  Google Scholar 

  25. Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities Blood 2000 95: 4008–4010

    CAS  PubMed  Google Scholar 

  26. Jagannath S, Vesole D, Siegel S et al. Final analysis of total therapy with tandem transplants for 231 newly diagnosed patients with multiple myeloma Blood 1997 90: 418a (Abstr. 1860)

    Google Scholar 

  27. Tricot G, Barlogie B, Jagannath S et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities Blood 1995 86: 4250–4256

    CAS  PubMed  Google Scholar 

  28. Tricot G, Sawyer JR, Jagannath S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants J Clin Oncol 1997 15: 2659–2666

    CAS  PubMed  Google Scholar 

  29. Rajkumar S, Fonseca R, Lacy M et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma Bone Marrow Transplant 1999 24: 497–503

    CAS  PubMed  Google Scholar 

  30. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999 93: 55–65

    CAS  PubMed  Google Scholar 

  31. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial Blood 1998 92: 3131–3136

    CAS  PubMed  Google Scholar 

  32. Gertz MA, Lacy MQ, Inwards DJ et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma Bone Marrow Transplant 2000 26: 45–50

    CAS  PubMed  Google Scholar 

  33. Harousseau JLM, Facon T, Moreau P et al. Comparison of high-dose melphalan 140 mg/m2 plus total body irradiation and high-dose melphalan 200 mg/m2 as conditioning regimen for peripheral blood progenitor cell autotransplantation in patients with newly diagnosed multiple myeloma. Preliminary results of the IFM 9502 randomized trial Blood 1999 94: (Abstr. 3150)

    Google Scholar 

  34. Moreau P, Facon T, Hulin C et al. Superiority of 200 mg/m2 melphalan (HDM200) over 8 Gy total body irradiation plus 140 mg/m2 melphalan (TBI + HDM140) as conditioning regimens for peripheral blood stem cell (PBSC) transplantation in patients with newly diagnosed multiple myeloma (MM). Final analysis of the IFM9502 randomized trial. VIIIth International Myeloma Workshop, p43, May 2001, Banff, Canada

  35. Desikan KR, Tricot G, Dhodapkar M et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone Bone Marrow Transplant 2000 25: 483–487

    CAS  PubMed  Google Scholar 

  36. Björkstrand B, Svensson H, Ljungman P et al. 2522 autotransplants in multiple myeloma: a registry study from the European Group for Blood and Marrow Transplantation (EBMT) Blood 1997 90: 419a (Abstr. 1862)

    Google Scholar 

  37. Björkstrand B, Hagman A, Ljungman P et al. Autologous stem cell transplantation in multiple myeloma: the 2000 EBMT registry update Bone Marrow Transplant 2001 27: (Suppl. 1) S40 (Abstr. OS203)

    Google Scholar 

  38. Lokhorst HM, Sonneveld P, Verdonck LF . Intensive treatment for multiple myeloma: where do we stand? Br J Haematol 1999 106: 18–27

    CAS  PubMed  Google Scholar 

  39. Rajkumar SV, Fonseca R, Lacy MQ et al. Beta 2-microglobulin and bone marrow plasma cell involvement predictcomplete responders among patients undergoing blood cell transplantation for myeloma Bone Marrow Transplant 1999 23: 1261–1266

    CAS  PubMed  Google Scholar 

  40. Rajkumar SV, Fonseca R, Lacy MQ et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma J Clin Oncol 1999 17: 1551–1557

    CAS  PubMed  Google Scholar 

  41. Rajkumar SV, Leong T, Roche PC et al. Prognostic value of bone marrow angiogenesis in multiple myeloma Clin Cancer Res 2000 6: 3111–3116

    CAS  PubMed  Google Scholar 

  42. Rajkumar SV, Fonseca R, Witzig TE et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma Leukemia 1999 13: 469–472

    CAS  PubMed  Google Scholar 

  43. Rajkumar SV, Fonseca R, Dispenzieri A et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma Bone Marrow Transplant 2000 26: 979–983

    CAS  PubMed  Google Scholar 

  44. Steensma DP, Gertz MA, Greipp PR et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death Blood 2001 97: 2522–2523

    CAS  PubMed  Google Scholar 

  45. Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma Blood 1999 93: 51–54

    CAS  PubMed  Google Scholar 

  46. Badros A, Zangari M, Desikan R et al. Feasibility and efficacy of melphalan-based high dose therapy (MEL-HDT) with autologous peripheral blood stem cell support for patients with multiple myeloma (MM) age ≥ 70 years Blood 1999 94: 578a (Abstr. 2579)

    Google Scholar 

  47. Palumbo A, Triolo S, Argentino C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients Blood 1999 94: 1248–1253

    CAS  PubMed  Google Scholar 

  48. Tricot G, Alberts DS, Johnson C et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study Clin Cancer Res 1996 2: 947–952

    CAS  PubMed  Google Scholar 

  49. Mehta J, Ayers D, Mattox S et al. High-dose melphalan and autotransplantation in myeloma with renal impairment: a matched-pair comparison with patients without renal failure Blood 1997 92: (Suppl. 1) 419a (Abstr. 1863)

    Google Scholar 

  50. Mehta J, Tricot G, Jagannath S et al. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant Bone Marrow Transplant 1997 20: 113–116

    CAS  PubMed  Google Scholar 

  51. Ballester OF, Tummala R, Janssen WE et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency Bone Marrow Transplant 1997 20: 653–656

    CAS  PubMed  Google Scholar 

  52. Gertz MA, Witzig TE, Pineda AA et al. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation Bone Marrow Transplant 1997 19: 337–342

    CAS  PubMed  Google Scholar 

  53. Stewart AK, Schiller G, Vescio R et al. CD34 selection does not prolong disease free or overall survival in myeloma patients undergoing autologous stem cell transplant: results of a phase III study Blood 1999 94: (Suppl. 1) 714a (Abstr. 3151)

    Google Scholar 

  54. Morineau N, Tang XW, Moreau P et al. Lack of benefit of CD34+ cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study Leukemia 2000 14: 1815–1820

    CAS  PubMed  Google Scholar 

  55. Lemoli RM, Martinelli G, Zamagni E et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy Blood 2000 95: 2234–2239

    CAS  PubMed  Google Scholar 

  56. Tricot G, Gazitt Y, Leemhuis T et al. Collection, tumorcontamination, and engraftment kinetics of highly purifiedhematopoietic progenitor cells to support high dose therapy inmultiple myeloma Blood 1998 91: 4489–4495

    CAS  PubMed  Google Scholar 

  57. Michallet M, Philip T, Philip I et al. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution Exp Hematol 2000 28: 858–870

    CAS  PubMed  Google Scholar 

  58. Vescio R, Schiller G, Stewart AK et al. Multicenter phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma Blood 1999 93: 1858–1868

    CAS  PubMed  Google Scholar 

  59. Harousseau JL, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of a French Registry on Autologous Transplantation in Multiple Myeloma Stem Cells 1995 13: (Suppl. 2) 132–139

    PubMed  Google Scholar 

  60. Harousseau JL, Milpied N, Laporte JP et al. Double-intensive therapy in high-risk multiple myeloma Blood 1992 79: 2827–2833

    CAS  PubMed  Google Scholar 

  61. Björkstrand B, Ljungman P, Bird JM et al. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma Bone Marrow Transplant 1995 15: 367–371

    PubMed  Google Scholar 

  62. Jagannath S, Vesole DH, Glenn L et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support Blood 1992 80: 1666–1672

    CAS  PubMed  Google Scholar 

  63. Tosi P, Cavo M, Zamagni E et al. A multicentric randomized clinical trial comparing single vs double autologous peripheral blood stem cell transplantation for patients with newly diagnosed multiple myeloma: results of an interim analysis Blood 1999 94: (Suppl. 1) 715a (Abstr. 3155)

    Google Scholar 

  64. Attal M, Harousseau JJL, Fancon TT et al. Single versus double transplantation in myeloma: a prospective randomized trial of the Inter Groupe Francophone du Myelome (IFM) Blood 2000 96: (Suppl. 1) 557a (Abstr. 2393)

    Google Scholar 

  65. Reece DE, Hale GA, Howard DS et al. Treatment of multiple myeloma (MM) patients (pts) with tandem autologous stem cell transplantation (ASCT) using high-dose (HD) melphalan (MEL) followed by busulfan (BU) Proc Am Soc Clin Oncol 2001 20: 15a (Abstr. 57)

    Google Scholar 

  66. Huijgens PC, Dekker-van Roessel HM, Jonkhoff AR et al. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma Bone Marrow Transplant 2001 27: 925–931

    CAS  PubMed  Google Scholar 

  67. Cavo M, Tosi P, Zamagni E et al. The ‘Bologna 96’ clinical trial of single vs. double PBSC transplantation for previously untreated MM: results of an interim analysis. VIIIth International Myeloma Workshop, S16, May 2001, Banff, Canada

  68. Fermand JP, Marolleau C, Alberti C et al. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). VIIIth International Myeloma Workshop, P61, May 2001, Banff, Canada

  69. Attal M, Harousseau JL, Facon T . Single versus double transplant in myeloma: a randomized trial of the ‘Inter Groupe Francais Du Myelome’ (IFM). VIIIth International Myeloma Workshop, S15, May 2001, Banff, Canada

  70. Segeren CM, Sonneveld P, Van der Hold B et al. Intensive versus double intensive therapy in previously untreated multiple myeloma: A prospective randomized phase III study in 450 patients. VIIIth International Myeloma Workshop, S17, May 2001, Banff, Canada

  71. Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells J Clin Oncol 1999 17: 208–215

    CAS  PubMed  Google Scholar 

  72. Majolino I, Corradini P, Scime R et al. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma Bone Marrow Transplant 1998 22: 449–455

    CAS  PubMed  Google Scholar 

  73. Martinelli G, Terragna C, Lemoli RM et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. VIIIth International Myeloma Workshop, P68, May 2001, Banff, Canada

  74. Lokhorst HM, Sonneveld P, Cornelissen JJ et al. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma Bone Marrow Transplant 1999 23: 317–322

    CAS  PubMed  Google Scholar 

  75. Björkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 1996 88: 4711–4718

    PubMed  Google Scholar 

  76. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation Blood 1997 90: 4206–4211

    CAS  PubMed  Google Scholar 

  77. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome J Clin Oncol 2000 18: 3031–3037

    CAS  PubMed  Google Scholar 

  78. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle Blood 1996 87: 1196–1198

    CAS  PubMed  Google Scholar 

  79. Verdonck LF, Lokhorst HM, Dekker AW et al. Graft-versus-myeloma effect in two cases Lancet 1996 347: 800–801

    CAS  PubMed  Google Scholar 

  80. Mehta J, Singhal S . Graft-versus-myeloma Bone Marrow Transplant 1998 22: 835–843

    CAS  PubMed  Google Scholar 

  81. Couban S, Stewart AK, Loach D et al. Autologous and allogeneic transplantation for multiple myeloma at a single centre Bone Marrow Transplant 1997 19: 783–789

    CAS  PubMed  Google Scholar 

  82. Mehta J, Ayers D, Mattox S et al. Allogeneic bone marrow transplantation in multiple myeloma: single-center experience of 97 patients Blood 1997 90: 225a (Abstr. 993)

    Google Scholar 

  83. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome Blood 1996 88: 2787–2793

    CAS  PubMed  Google Scholar 

  84. Schlossman RL, Webb I, Aleya EP et al. Similar disease-free survival (DFS) after allografting and autografting for multiple myeloma (MM) Blood 1997 90: 226a (Abstr. 994)

    Google Scholar 

  85. Zamagni E, Cellini C, Ronconi S et al. Progress in allogeneic stem cell transplantation for multiple myeloma over the 90's. VIIIth International Myeloma Workshop, P69, May 2001, Banff, Canada

  86. Gahrton G, Apperley J, Bacigalupo A et al. An overview of allogeneic transplantation in multiple myeloma. VIIIth International Myeloma Workshop, S14, May 2001, Banff, Canada

  87. Ballen K, King R, Carston M et al. Outcome of unrelated transplants in patients with multiple myeloma Blood 2000 96: 414a (Abstr. 1780)

    Google Scholar 

  88. Bensinger, WI, Buckner D, Gahrton G . Allogeneic stem cell transplantation for multiple myeloma Hematol Oncol Clin North Am 1997 11: 147–157

    CAS  PubMed  Google Scholar 

  89. Mehta J, Tricot G, Jagannath S et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998 21: 887–892

    CAS  PubMed  Google Scholar 

  90. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 1997 15: 433–444

    PubMed  Google Scholar 

  91. Porter DL, Collins RH Jr, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions Blood 2000 95: 1214–1221

    CAS  PubMed  Google Scholar 

  92. Bertz H, Burger JA, Kunzmann R et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect Leukemia 1997 11: 281–283

    CAS  PubMed  Google Scholar 

  93. Alyea EP, Soiffer RJ, Cunning C et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplantation Blood 1998 91: 3671–3688

    CAS  PubMed  Google Scholar 

  94. Lokhorst HM, Liebowitz D . Adoptive T-cell therapy Semin Hematol 1999 36 (1 Suppl. 3): 26–29

    Google Scholar 

  95. Lokhorst H . Graft versus myeloma. Clinical and basic aspects. VIIIth International Myeloma Workshop, S20, May 2001, Banff, Canada

  96. Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma Bone Marrow Transplant 2000 26: 1179–1184

    CAS  PubMed  Google Scholar 

  97. Munshi NC, Govindarajan R, Drake R et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir Blood 1997 89: 1334–1340

    CAS  PubMed  Google Scholar 

  98. Dilber MS, Abedi MR, Björkstrand B et al. Suicide gene therapy for plasma cell tumors Blood 1996 88: 2192–2200

    CAS  PubMed  Google Scholar 

  99. Champlin R, Khouri I, Kornblau S et al. Reinventing bone marrow transplantation: nonmyeloablative preparative regimens and induction of graft-versus-malignancy effect Oncology 1999 13: 621–628

    CAS  PubMed  Google Scholar 

  100. Badros A, Barlogie B, Morris C et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions Blood 2001 97: 2574–2579

    CAS  PubMed  Google Scholar 

  101. Barlogie B, Tricot G, Shaughnessy J, Epstein J . Toward curing myeloma: keeping the pressure on tumor cells and the microenvironment with high dose melphalan and thalidomide. VIIIth International Myeloma Workshop, S65, May 2001, Banff, Canada

  102. Lalancette L, Rezvani K, Szydlo R et al. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: the EBMT experience Blood 2000 96: 204a (Abstr. 872)

    Google Scholar 

  103. Simpson D, Berkahn LC, Raptis A, Klingemann H-G . Fludarabine/melphalan regimen results in low treatment related mortality and low relapse in myeloma patients undergoing allogeneic stem cell transplant (BMT) Blood 2000 96: 409a (Abstr. 1762)

    Google Scholar 

  104. Peggs KS, Williams CD, Chopra R et al. Non-myeloblative allogeneic transplantation with adjuvant dose escalated donor lymphocyte infusions for multiple myeloma Blood 2000 96: 781a (Abstr. 3379)

    Google Scholar 

  105. Molina A, Sahebi F, Maloney DG et al. Non-myeloablative peripheral blood stem cell (PBSC) allografts following cytoreductive autotransplants for treatment of multiple myeloma (MM) Blood 2000 96: (Suppl. 1) 480a (Abstr. 2063)

    Google Scholar 

  106. Kroeger N, Renges H, Krueger W et al. Non-myeloablative allograft to induce graft versus myeloma effect after cytoreductive autotransplant for multiple myeloma Blood 2000 96: 782a (Abstr. 3383)

    Google Scholar 

  107. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 2001 97: 3390–400

    CAS  PubMed  Google Scholar 

  108. Amelia Island Conference on Multiple Myeloma, January 2001, and S Giralt (personal communication)

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

    DH Vesole

  2. Department of Medicine, Comprehensive Cancer Center of the University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH, USA

    A Simic & HM Lazarus

Authors
  1. DH Vesole
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Simic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. HM Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vesole, D., Simic, A. & Lazarus, H. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts. Bone Marrow Transplant 28, 725–735 (2001). https://doi.org/10.1038/sj.bmt.1703254

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703254

Keywords

This article is cited by

Search

Advanced search

Quick links